Evidence map›Paper›PMID 37234399›Full record

ArticleFujita medical journal2023

Dry loop-mediated isothermal amplification assay for detection of SARS-CoV-2 from clinical specimens.

Yuki Higashimoto, Masaru Ihira, Yoshiki Kawamura, Masato Inaba, Kazuya Shirato, Tadaki Suzuki, Hideki Hasegawa, Tsutomu Kageyama, Yohei Doi, Tadayoshi Hata and 1 more

Abstract read
In one paragraph

Article in Fujita medical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Diagnostic accuracy of LAMP versus PCR over the course of SARS-CoV-2 infection.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuki HigashimotoFaculty of Medical Technology, Fujita Health University, School of Medical Sciences, Toyoake, Aichi, Japan.
Masaru IhiraFaculty of Clinical Engineering, Fujita Health University, School of Medical Sciences, Toyoake, Aichi, Japan.
Yoshiki KawamuraDepartment of Pediatrics, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Masato InabaDepartment of Infectious Diseases, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Kazuya ShiratoDepartment of Virology III, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.
Tadaki SuzukiDepartment of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.
Hideki HasegawaInfluenza Virus Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.
Tsutomu KageyamaInfluenza Virus Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.
Yohei DoiDepartment of Infectious Diseases, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Tadayoshi HataFaculty of Medical Technology, Fujita Health University, School of Medical Sciences, Toyoake, Aichi, Japan.
Tetsushi YoshikawaDepartment of Pediatrics, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To establish a point-of-care test for coronavirus disease 2019 (COVID-19), we developed a dry loop-mediated isothermal amplification (LAMP) method to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA. Methods: We carried out reverse transcription (RT)-LAMP using the Loopamp SARS-CoV-2 Detection kit (Eiken Chemical, Tokyo, Japan). The entire mixture, except for the primers, is dried and immobilized inside the tube lid. Results: To determine the specificity of the kit, 22 viruses associated with respiratory infections, including SARS-CoV-2, were tested. The sensitivity of this assay, determined by either a real-time turbidity assay or colorimetric change of the reaction mixture, as evaluated by the naked eye or under illumination with ultraviolet light, was 10 copies/reaction. No LAMP product was detected in reactions performed with RNA from any pathogens other than SARS-CoV-2. After completing an initial validation analysis, we analyzed 24 nasopharyngeal swab specimens collected from patients suspected to have COVID-19. Of the 24 samples, 19 (79.2%) were determined by real-time RT-PCR analysis as being positive for SARS-CoV-2 RNA. Using the Loopamp SARS-CoV-2 Detection kit, we detected SARS-CoV-2 RNA in 15 (62.5%) of the 24 samples. Thus, the sensitivity, specificity, positive predictive value, and negative predictive values of the Loopamp 2019-CoV-2 detection reagent kit were 78.9%, 100%, 100%, and 55.6%, respectively. Conclusions: The dry LAMP method for detecting SARS-CoV-2 RNA is fast and easy to use, and its reagents can be stored at 4°C, solving the cold chain problem; thus, it represents a promising tool for COVID-19 diagnosis in developing countries.

Indexed as

COVID-19LAMPReal-time RT-PCRSARS-CoV-2

Identifiers

PMID37234399
PMCPMC10206895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.